Print page content Print
Increase text size Decrease text size
Text Size

Together, we continue to change the way we approach canine pruritus.

Together, we continue to change way we approach canine pruritus.

Itch can erode cherished bonds...
and treatment has historically required trade-offs between efficacy, safety and cost

Itch takes an emotional toll on owners—and can affect their
relationships with the veterinarian

  • Itch is the #1 reason for veterinary visits1
  • 88% of owners have tried at-home itch treatments (up to 15 treatments) before bringing dog to the clinic2
  • Owners see veterinarians for real relief, immediately—rather than recommendations for treatments they could have tried at home3

Achieve a diagnosis and provide individualized care to protect the bonds that matter most

Start with foundational relief

Apoquel logo
Simparica logo
Convenia logo
Apoquel logo and/or Cytopoint logo
Start with foundational relief
Provide allergic itch relief throughout the diagnostic workup
Apoquel logo and/or Cytopoint logo
Plan for long-term management

Tailor your approach with the 2 best-in-class options for allergic itch relief

  • Fast relief reassures the owner, inspires trust in the veterinarian
  • The right itch treatment helps you diagnose to completion by allowing the workup to proceed without interference—while providing patient relief and comfort

For rapid relief you can start and stop

Starts providing itch relief within 4 hours4

Targets itch and inflammatory cytokines, resulting in significant reduction of pruritus and inflammation5

Can be used long term for maintenance therapy and with many other medications, including NSAIDs, anti-infectives, parasiticides, antifungals and allergen-specific therapy6*

Allows flexibility to stop and start control of pruritus quickly—as necessary—for assessments during the diagnostic workup (eg, flea and food trials)

APOQUEL is a great choice for:

rapid allergic itch relief4

start-and-stop itch control

use during diagnostic tests7

dogs at least 12 months of age

management of pruritic flares

short- and long-term management of itch

*The use of APOQUEL has not been evaluated in combination with other systemic immunosuppressants, such as corticosteroids and cyclosporine

For sustained, long-lasting relief

Begins to relieve itch within 24 hours and lasts for 4 to 8 weeks8

Can be used in dogs with concomitant disease or in combination with other commonly used medications, including APOQUEL9

Targets and neutralizes interleukin (IL)-31, a key itch-inducing cytokine in allergic and atopic dermatitis10

Provides long-lasting relief with a single in-office injection, ensuring compliance8

CYTOPOINT is a great choice for:

dogs who are difficult to pill or cases in which owner compliance is a concern

dogs with comorbidities

owners who seek
non-drug therapy

dogs of all ages

management of pruritic flares

dogs requiring lasting,
lifelong disease management

With the right approach, veterinarians can get back to doing what they love…caring for animals

See how transforming the approach to the pruritic dog protects the bonds that matter

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL IMPORTANT SAFETY INFORMATION: Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

SIMPARICA TRIO INDICATIONS: SIMPARICA TRIO is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections. SIMPARICA TRIO kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.

SIMPARICA TRIO IMPORTANT SAFETY INFORMATION: Use with caution in dogs with a history of seizures. SIMPARICA TRIO contains sarolaner, a member of the isoxazoline class, which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of SIMPARICA TRIO has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

For more information, please see the full Prescribing Information.

CONVENIA INDICATIONS: CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

CONVENIA IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia, and lethargy.

For more information, please see the full Prescribing Information.

CYTOPOINT INDICATIONS: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

References: 1. Now from Nationwide®. Most Common Medical Conditions that Prompt Veterinary Visits. Accessed December 18, 2018. 2. Data on file, Pet Owner Quantitative Market Research, 2013, Zoetis Inc. 3.Data on file, Pruritus Market Opportunity, 2015, Zoetis Inc. 4. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518. doi:10.1111/vde.12166. 5. Gonzales AJ, 9 of 41 Bowman J, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324. doi:10.1111/jvp.12101. 6. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194. 7. Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297. 8. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc. 9. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc. 10. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2020 Zoetis Services LLC. All rights reserved. ZPC-00064R3



We are Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2020 Zoetis Services LLC. All rights reserved.